Science-Led. Market-Focused. Mission-Driven.

Our leadership team brings experience across early discovery, clinical development, regulatory strategy, and commercialization—reducing execution risk across the full development lifecycle.

Our team of scientists, biotech entrepreneurs, veterinarians, and industry strategists form a unique blend of scientific insight, commercial experience, and cross-sector collaboration. We’re purpose-built to drive innovation from lab to market. Together, we're shaping a bold path to commercialization with the clarity, credibility, and execution that investors can trust.

  • George has led Network Immunology since the advent of the Company’s AbstimX™ platform technology and therapy, taking it from the concept stage to the veterinary clinical stage and to the verge of licensing and commercialization. He has led the raise of approximately CAD $2M and built an outstanding Executive Team to commercialize NI’s world-changing AbstimX™ technology. George has 15 years of full-time experience in biotech business administration, capital raising, strategic corporate development, and building executive and scientific teams.

  • Douglas has a proven track record of driving brand and product success across various industries, including stem cell medicine, hydrogen energy, 3D Printing, and So Good/So Nice Soy beverage in North America. His expertise in corporate development, investor relations, and appropriate capital infusion has been pivotal in elevating Network Immunology’s position in the biotech market.

  • Natalia Meissner is a Switzerland-based CFO with 25+ years of experience in high-growth, tech-driven industries. She brings deep expertise in M&A integration, financial performance, and operational optimization, backed by an MBA, CPA, and PMI certifications. Known for driving value through strategic planning and sustainability-focused initiatives.

  • Helio has served in corporate development capacities for a number of companies and has a strong aptitude for operations. He offers a scientific business development strategy, including therapeutic portfolio development, innovative products, licensing opportunities, regulatory feasibility, marketing, and access analysis. MBA in Health Economics and Health Systems. Previously, he served as President of the SBMF (Brazilian Association of Pharmaceutical Medicine), a medical society that congregates health professionals working in the pharmaceutical industry.

  •  Anthony holds over two decades of business, operations, product development, and scientific experience with a sound clinical understanding in personalised Medicine, Drug and Biomarker Development, Health and Wellness (Food), Autoimmunity, Gastroenterology, Pathology, and Oncology.

    He has served in corporate development capacities for a number of companies, and has a strong aptitude for operations.

  • Aaron brings over 15 years of experience in health and management consulting, blending operational excellence with mission-driven innovation. As head of operations, he builds resilient systems that drive impact, streamline execution, and advance Network Immunology’s mission to strengthen immune systems worldwide.

  •  Hadley is a seasoned science communicator with a background academic research. Passionate about bridging the gap between science and the public, Hadley seeks to integrate science communication into Network Immunology’s initiatives, fostering meaningful connections and promoting awareness of our innovative immunotherapeutic solutions for inflammatory diseases.

  • Dr. Born is a naturopathic physician and Certified Nutrition Specialist (CNS), serving as co-owner and Chief Medical Officer of Born Integrative Medicine Specialists, PLLC. He acts as a key opinion leader for Augurex Life Sciences Corp, provides naturopathic care for Karma Docs, and serves as a medical advisor to Kale Diagnostics. Additionally, Dr. Born is recognized as an expert consultant and advisor, both domestically and internationally, to the dietary supplement industry.

    Dr. Born’s clinical focus is utilizing integrative medicine to treat families of all ages who have complex chronic diseases, with a strong interest in difficult and refractory cases of any condition and age. He treats patients throughout the United States and worldwide.

  • Dr. Chukwuemeka Oko is a physician-scientist with over a decade of experience advancing immunology-driven diseases in gastroenterology, hepatology, oncology, and immune dysregulation. He translates discoveries into patient-focused, clinically credible programs, with specialized expertise in GI mucosal immunology and IBD. At leading medical centers, he has guided protocol design, operational readiness, site activation, recruitment optimization, data quality oversight, and publication of abstracts and peer-reviewed manuscripts. Collaborating with global biopharma and contract research organizations, he ensures execution, monitoring, and data integrity. In medical affairs, Dr. Oko leads compliant scientific exchanges, KOL engagement, and converts field insights into evidence plans, congress strategies, advisory boards, and educational resources. Holding an MBA and certifications in pharmacovigilance and pharmaceutical disciplines, he integrates safety stewardship, budget planning, and health economics to deliver rigorous science with compassionate, measurable outcomes and timely patient access.

  • A physician-scientist and biotechnology leader with 25 years of experience driving translational research and product commercialization from concept to clinic. My career is built on a deep understanding of complex biological systems, from molecular discovery and epigenetics to clinical immunology and stem cell therapy. I have a proven track record of leading R&D initiatives, managing clinical operations, and navigating the regulatory and commercial pathways required to bring novel therapies to market. I am positioned to provide strategic advisory on clinical development, regulatory strategy, and therapeutic application for Network Immunology's AbstimX™ platform.

PHOTO TO COME

  • Carlos Andrés Alvarado is a physician with a master’s degree in Health Economics and Pharmacoeconomics and a graduate of the University of California, Irvine, where he completed a specialized program in Healthcare and Public Health Analytics focused on the application of artificial intelligence and data science to healthcare systems. He has more than 15 years of experience in the pharmaceutical industry, holding leadership roles at Roche, Takeda, and Johnson & Johnson (J&J), where he led regional medical teams and supported late-stage development and post-marketing programs in oncology, immunology, and neuroscience. His professional work has centered on evidence generation, scientific communication, regulatory compliance, and cross-functional collaboration between medical, commercial, and R&D teams.

  • A financial analyst with over 15 years of experience in private equity across multiple industries, Miika provides the company with comprehensive expertise in securities compliance, investor relations, and corporate governance. His extensive background in capital markets and regulatory matters ensures the company maintains the highest standards of compliance and transparency in its dealings with investors and regulatory bodies.

  • John’s extensive leadership experience is characterized by a commitment to operational excellence and strategic growth. With a passion for innovation and a globetrotting spirit, he ensures that Network Immunology remains at the forefront of the biotech industry.

  • Randy brings over 20 years of leadership experience in business development, sales, and marketing within the veterinary and biotech industries. His expertise in optimizing commercial operations positions the company for strong global growth.

  • With two decades in the health industry, Henrique has forged significant pharmaceutical partnerships and spearheaded international business development initiatives, positioning him as force in bringing Network Immunology’s technologies to the global market.

  • Alexis specializes in the development and commercialization of animal health therapies. As veterinary doctor with 26 years of experience in animal therapeutic development and an additional 9 in human therapeutic development, he leads Network Immunology's advancement of immuno-therapeutics for inflammatory diseases in animals while furthering the vision and plan of applying NI's technology to human clinical applications. His strategic, collaborative approach enhances our innovation, steering Network Immunology towards significant global impact with both veterinary and human medicine.